FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 11:57:25 14/06/2024 pm IST | ||
| 19.47 EUR | +1.51% |
|
| Current month | +15.55% | ||
| 1 month | +28.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 19.47 | +1.51% |
| 13/24/13 | 19.18 | +2.08% |
| 12/24/12 | 18.79 | -3.19% |
| 11/24/11 | 19.41 | -0.41% |
| 10/24/10 | 19.49 | -0.10% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 11:57 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GK8UJT |
| ISIN | DE000GK8UJT1 |
| Date issued | 08/08/2022 |
| Strike | 239.5 $ |
| Maturity | Unlimited |
| Parity | 11.7 : 1 |
| Emission price | 10.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.59 € |
|---|---|
| Lowest since issue | 8.36 € |
| Spread | 0.15 € |
| Spread % | 0.77% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat
